LRCX vs MRNA
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Nov 01, 2026
LRCX
MRNA
Investment Advisor Scores
MRNA
AI Analyst Insights
Detailed Metrics Comparison
| Metric | LRCX | MRNA | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 26.3158 | 23.0415 | MRNA |
| PEG Ratio | 1.1063 | 0 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 54.4% | 2.1% | LRCX |
| Earnings Growth | 76.6% | -85.1% | LRCX |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 66.8/100 | 52.8/100 | LRCX |
| Profit Margin | 32.3% | -141.4% | LRCX |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | HOLD | HOLD | Tie |
Relative Price Performance (Last 90 Days)
Current Technical Phase
LRCX
MarkdownPrice below a falling SMA50 (slope -3.8%), weak momentum, RSI 34
MRNA
MarkupPrice above SMA50, rising 50-day trend (47.6% over 20 days), RSI 57
Fundamentals Snapshot
| Metric | LRCX | MRNA |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 29.2 | -45.3 |
| Trailing P/E | 37.9 | — |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.5% | 0.0% |
| Gross Margin | 0.5% | -0.7% |
| Operating Margin | 0.4% | -5.6% |
| EPS | 6.71 | -7.98 |
| Dividend Yield | 0.00% | — |